Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TNYA |
---|---|---|
09:32 ET | 2020 | 3.58 |
09:36 ET | 136 | 3.6295 |
09:38 ET | 250 | 3.6243 |
09:41 ET | 300 | 3.61 |
09:43 ET | 100 | 3.615 |
09:45 ET | 306 | 3.5952 |
09:52 ET | 151 | 3.59 |
09:54 ET | 10815 | 3.56 |
09:56 ET | 2086 | 3.54 |
09:57 ET | 100 | 3.56 |
10:01 ET | 200 | 3.55 |
10:03 ET | 797 | 3.56 |
10:08 ET | 200 | 3.565 |
10:14 ET | 500 | 3.555 |
10:15 ET | 1452 | 3.58 |
10:17 ET | 200 | 3.585 |
10:21 ET | 100 | 3.59 |
10:24 ET | 298 | 3.59 |
10:26 ET | 2743 | 3.59 |
10:28 ET | 100 | 3.59 |
10:30 ET | 100 | 3.59 |
10:32 ET | 200 | 3.595 |
10:33 ET | 2211 | 3.585 |
10:35 ET | 200 | 3.59 |
10:39 ET | 10800 | 3.59 |
10:44 ET | 228 | 3.61 |
10:46 ET | 318 | 3.605 |
10:48 ET | 100 | 3.605 |
10:50 ET | 200 | 3.61 |
10:53 ET | 300 | 3.61 |
10:55 ET | 700 | 3.59 |
10:57 ET | 731 | 3.57 |
11:00 ET | 200 | 3.565 |
11:02 ET | 800 | 3.56 |
11:06 ET | 400 | 3.56 |
11:08 ET | 102 | 3.57 |
11:13 ET | 300 | 3.57 |
11:15 ET | 580 | 3.57 |
11:20 ET | 200 | 3.57 |
11:26 ET | 218 | 3.57 |
11:31 ET | 1520 | 3.5601 |
11:33 ET | 1641 | 3.57 |
11:44 ET | 1230 | 3.56 |
11:45 ET | 600 | 3.565 |
11:47 ET | 2759 | 3.56 |
11:49 ET | 100 | 3.56 |
11:54 ET | 1100 | 3.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tenaya Therapeutics Inc | 330.6M | -2.2x | --- |
Zura Bio Ltd | 334.3M | -2.6x | --- |
Skye Bioscience Inc | 325.9M | -2.4x | --- |
Ventyx Biosciences Inc | 337.0M | -1.0x | --- |
Replimune Group Inc | 323.7M | -2.3x | --- |
Fractyl Health Inc | 322.8M | -3.7x | --- |
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $330.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 78.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.65 |
Book Value | $2.04 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.